Ranbaxy Internal Audit Disclosure Highlights FDA Policy Exceptions
This article was originally published in The Gold Sheet
Executive Summary
FDA went to court for a look at Ranbaxy’s internal audits despite its longstanding policy against routinely reviewing such documents. However, a 1996 revision made exceptions for cases like Ranbaxy’s, in which the agency is pursuing allegations of fraud.
You may also be interested in...
FDA Focuses Latest Warnings on Accountability and Root Cause
Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?
FDA Focuses Latest Warnings on Accountability and Root Cause
Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?
Data Integrity Problems Continued to Surface in Recent Warning Letters
Recent GMP warning letters featured data integrity issues.